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Objectives We studied whether functional improvement after cardiac resynchronization therapy (CRT) is associated with
reversal of the heart failure (HF) gene program.
Background Cardiac resynchronization therapy improves exercise tolerance and survival in patients with advanced congestive
HF and dyssynchrony.
Methods Twenty-four patients referred for CRT underwent left ventricular (LV) endomyocardial biopsies immediately be-
fore CRT implantation (baseline). In addition, 17 of them underwent LV endomyocardial biopsy procurement 4
months later (follow-up). In 6 control patients with normal LV function, LV biopsies were obtained at the time of
coronary artery bypass grafting. The LV messenger ribonucleic acid (mRNA) levels of contractile and calcium
regulatory genes were measured by quantitative real time polymerase chain reaction and normalized for glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH). The HF patients showing an improvement in New York Heart
Association (NYHA) functional class by 1 score and a relative increase in LV ejection fraction 25% at 4
months after CRT were considered as responders.
Results The HF patients were characterized by lower LV mRNA levels of -myosin heavy chain (-MHC), -myosin heavy
chain (-MHC), sarcoplasmic reticulum calcium ATPase 2 (SERCA), phospholamban (PLN), and higher brain
natriuretic peptide (BNP) mRNA levels as compared with control subjects. Responders to CRT (n  11) showed
an increase in LVEF (p  0.001), a decrease in left ventricular end-diastolic diameter (p  0.003), and NYHA
functional class (p  0.002), and a reduction in N-terminal proBNP levels (p  0.032) as compared with base-
line. This was associated with an increase in mRNA levels of -MHC (p  0.035), SERCA (p  0.032), a de-
crease in BNP mRNA levels (p  0.002), and an increase in the ratio of -/-MHC (p  0.018) and SERCA/PLN
(p  0.012). No significant changes in molecular profile were observed in nonresponders.
Conclusions In HF patients with electromechanical cardiac dyssynchrony, functional improvement related to CRT is associ-
ated with favorable changes in established molecular markers of HF, including genes that regulate contractile
function and pathologic hypertrophy. (J Am Coll Cardiol 2008;51:129–36) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.087w
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che adverse left ventricular (LV) remodeling and the
educed contractile function observed in heart failure (HF)
s associated with altered gene expression profile. One of
he hallmarks of the altered molecular response is the
ctivation of the “fetal” gene program including isoform
witch in myosin heavy chain (MHC) gene expression
rom the Cardiovascular Center, Molecular Cardiology Unit and Cardiovascular
esearch Center, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium.a
Manuscript received March 29, 2007; revised manuscript received July 2, 2007,
ccepted July 3, 2007.ith down-regulation of the fast -myosin isoform (1–3)
nd up-regulation of natriuretic peptides. Other molec-
lar changes include alterations in expression of genes
See page 137
ncoding excitation-contraction coupling such as sarco-
lasmic reticulum calcium ATPase 2 (SERCA) and phos-
holamban (PLN). End-stage HF is associated with de-
reased levels of SERCA relative to PLN as well as reduced
ctivity, resulting in impaired calcium cycling thereby ac-
(
f
a
s

p
b
m
a
t
i
i
r
i
w
e
m
M
S
c
t
w
i
m
m
h
a
u
d
s
b
s
D
e
i
w
c
s
a
d
w
B
i
L
a
p
b
(
D
e
S
s
o
f
f
g
(
L
u
s
Q
i
v
b
w
s
d
E
d
a
F
S
u
m
w
w
c
l
a
B
p
D
b
a
D
130 Vanderheyden et al. JACC Vol. 51, No. 2, 2008
Myocardial Gene Expression and CRT January 15, 2008:129–36counting for the contractile def-
icit of the failing heart (4). These
changes seem to represent basic
molecular mechanisms underlying
LV dysfunction and HF. Accord-
ingly, it was postulated that clinical
strategies should be designed to
target these adverse molecular
changes in order to effectively im-
prove contractile performance of
the failing myocardium (5).
Few clinical studies have ad-
dressed the reversibility of ad-
verse molecular profile in human
HF. In terminal HF, unloading
with LV assist devices resulted in
a decrease in cellular hypertrophy
and fibrosis in parallel with de-
activation of the “fetal” gene pro-
gram and improvements in myo-
cyte contractile properties and
beta-adrenergic responsiveness
6–9). In addition, in idiopathic dilated cardiomyopathy,
unctional improvement related to beta-blocker therapy was
ssociated with an increase in SERCA and -MHC mes-
enger ribonucleic acid (mRNA) together with a decrease in
-MHC mRNA (10).
Cardiac resynchronization therapy (CRT) acutely im-
roves cardiac performance by restoring the coordination
etween left and right ventricles, leading to improved
echanical efficiency in parallel with improved contraction
nd relaxation (11). These effects seem to be persistent over
ime and translate into a reversal of LV remodeling and
mproved clinical prognosis (12–14). However, alterations
n the molecular fingerprint associated with this reversed
emodeling have not been elucidated. Accordingly, we
nvestigated whether functional improvement after CRT
as associated with favorable changes in expression of
stablished molecular structural and calcium regulatory
arkers of HF.
ethods
tudy population. The study population consisted of 24
onsecutive New York Heart Association (NYHA) func-
ional class III to IV patients undergoing CRT. Patients
ere studied the day before and 4 months after CRT
mplantation. All patients had to be on optimal stable
edical therapy for at least 3 months and all cardiovascular
edications, comprising angiotensin-converting enzyme in-
ibitors (n  24), beta-blockers (n  23), aldosterone
ntagonists (n  20), and diuretics (n  24), were contin-
ed during the study period. Only the dose of the loop
iuretics was changed during follow-up. All patients were in
inus rhythm, had an LV ejection fraction (EF) 35%, left
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
CRT  cardiac
resynchronization therapy
HF  heart failure
LV  left ventricle/
ventricular
MHC  myosin heavy chain
mRNA  messenger
ribonucleic acid
Nt-proBNP  N-terminal
part of the pro-brain
natriuretic peptide
PLN  phospholamban
RT-PCR  real-time
polymerase chain reaction
SERCA  sarcoplasmic
reticulum calcium
ATPase 2undle branch block with QRS duration 140 ms, and dignificant mechanical dyssynchrony assessed by tissue
oppler echocardiography (15). All patients underwent LV
ndomyocardial biopsy sampling at baseline before CRT
mplantation. In 17 patients, LV endomyocardial biopsies
ere obtained at baseline and 4 months after CRT. The
ontrol group consisted of 6 patients with normal LV
ystolic and diastolic function undergoing elective coronary
rtery bypass grafting, owing to stable coronary artery
isease. All patients gave informed consent, and the study
as approved by the institutional ethics committee.
iventricular pacemaker implantation. Biventricular pac-
ng devices were implanted as previously described (16). The
V pacing electrode was positioned with a transvenous
pproach through the coronary sinus into the lateral or
osterolateral cardiac vein. The device was programmed in
iventricular-DDD mode with a fixed atrioventricular delay
115  24 ms) optimized by echocardiography (17).
oppler echocardiography. Two-dimensional Doppler
chocardiography was performed (Acuson Sequoia C512,
iemens, Malvern, Pennsylvania). Images were acquired in
emi-supine position at rest by 2 experienced echocardi-
graphers blinded to the moment of study examination. The
ollowing morphological and functional analyses were per-
ormed off-line from digitally-stored images: mitral regur-
itation, assessed semi-quantitatively on a scale of 1 to 4
18); LV end-diastolic and -systolic volumes; diameters; and
VEF, with the Simpson’s formula (19).
In addition, pulsed-wave tissue Doppler imaging was
sed to assess interventricular and LV intraventricular dys-
ynchrony from regional time intervals between the onset of
RS complex and the onset of systolic myocardial velocity
n basal segments of the left and right ventricle. Left
entricular dyssynchrony was defined as the maximum delay
etween basal LV segments. Interventricular dyssynchrony
as assessed by comparison of the most delayed basal
egment of the left ventricle with the right ventricle free wall
elay (15,17).
ndomyocardial biopsies. Left ventricular endomyocar-
ial biopsies were obtained with a long guiding sheath and
disposable transfemoral bioptome (Cordis Corp., Miami,
lorida) at the level of the distal interventricular septum.
eventeen patients consented at the time of enrollment to
ndergo repeat biopsies after 4 months. Control LV endo-
yocardial biopsies (n 6) were obtained from the free LV
all at the time of coronary artery bypass grafting in patients
ith normal LV function before initiation of extracorporeal
irculation. In all patients, biopsies were snap frozen in
iquid nitrogen and stored at 80°C for subsequent RNA
nalyses.
rain natriuretic peptide. Venous levels of N-terminal
ro-brain natriuretic peptide (BNP) (Elecsys 2010, Roche
iagnostics, Mannheim, Germany) were determined from
lood samples collected the day before CRT implantation
nd 4 months later.
ata analysis. Four months after CRT, patients were
ivided into 2 groups according to their response to CRT.
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January 15, 2008:129–36 Myocardial Gene Expression and CRTesponders were identified by a relative increase in EF of
25% together with an improvement in NYHA functional
lass score 1 (15,20). LV mRNA levels of -MHC,
-MHC and BNP, SERCA, and PLN all established
olecular markers of heart failure were analyzed.
uantitative real-time reverse transcriptase polymerase
hain reaction (RT-PCR). Highly sensitive RT-PCR was
sed for RNA quantifications as previously described (21).
riefly, total RNA was isolated from LV endomyocardial
iopsies with the RNeasy Fibrous Tissue Mini Kit (Qiagen,
alencia, California) and deoxyribonuclease digested. The
NA was reverse transcribed with random primers with
he high-capacity complementary deoxyribonucleic acid
cDNA) Archive Kit (Applied Biosystems, Foster City,
alifornia). The RT-PCR was performed in 96-well plates
n the ABI Prism 7000 Sequence Detection System (Applied
iosystems) with TaqMan Universal PCR Master Mix
nd Assays-On-Demand (Applied Biosystems), with a
nal reaction volume of 25 l. The PCR primers and
-carboxyfluorescein (FAM) probes for all of the target
enes were purchased as Assays-On-Demand. The assay
umbers for the target genes were Hs01564008_m1,
s00160179_m1, Hs00411899_m1, Hs01110632_m1, and
s00173590_m1 for SERCA, PLN, -MHC, -MHC,
nd BNP, respectively. Human glyceraldehyde 3-phosphate
ehydrogenase (GAPDH) gene was used as endogenous
ontrol (Applied Biosystems). All samples were performed
n triplicate. The relative expression of the target genes was
ormalized to the level of GAPDH in the same cDNA.
tatistical analysis. Data are expressed as mean SEM or
s median. An exact Wilcoxon signed-rank test, a Mann-
hitney test, and a Spearman correlation coefficient were
sed for appropriate comparisons. A p value of 0.05 was
onsidered significant for comparisons and correlations.
esults
aseline characteristics. Table 1 shows baseline clinical
haracteristics. All patients had severe LV dysfunction,
ignificant intraventricular and interventricular dyssyn-
hrony, and severe LV dilatation. All were in NYHA
unctional class 3 HF. Heart failure was due to ischemic
eart disease in 13 patients and idiopathic dilated cardio-
yopathy in 11 patients. All patients were receiving optimal
edical therapy that remained unchanged at follow-up. All
ontrol patients had normal LV function with stable coro-
ary artery disease; none of them had a history of acute
oronary syndrome.
aseline LV endomyocardial gene expression: HF pa-
ients versus control population. Table 2 shows LV gene
xpression of the entire study population. No infiltrative or
nflammatory processes were identified at diagnostic his-
opathological analysis. As expected, HF patients showed
ower levels of mRNA for SERCA, PLN, -myosin, and
-MHC and higher levels of BNP mRNA compared with
ontrol subjects. The ratio of SERCA to PLN was signif- tcantly lower in the HF patients compared with the control
roup. No differences in myocardial gene expression were
oted between patients with ischemic and nonischemic
ilated cardiomyopathy (data not shown). In the entire
tudy population, LVEF was inversely related to BNP
RNA (r  0.615; p  0.003) and directly related to
ERCA mRNA (r  0.660; p  0.001).
ffects of CRT on ventricular function and myocardial
ene expression. Table 3 shows serial changes in echocar-
iographic indices and myocardial gene expression in 17 HF
atients undergoing serial LV biopsies. Cardiac resynchro-
ization therapy overall resulted in a significant increase in
VEF together with a decrease in LV dimensions and
olumes. This was associated with a reduction in mitral
egurgitation, cardiac dyssynchrony, and serum N-terminal
art of the pro-brain natriuretic peptide (Nt-proBNP)
evels. Consequently, NYHA functional class decreased in
ll but 4 patients. In the entire patient population, LV BNP
RNA levels significantly decreased 4 months after CRT,
hereas no significant changes were observed in the expres-
ion of contractile or Ca2-regulating genes.
yocardial gene expression in responders versus nonre-
ponders to CRT. Table 4 and Figures 1 and 2 summarize
he effects of CRT upon LV function and gene expression in
esponders versus nonresponders. By definition responders
ere identified by a relative increase in EF of 25%
ogether with an improvement in NYHA functional class
core 1 (15,20). At baseline, responders and nonre-
ponders had similar LVEF and volumes. Nonresponders
aseline Characteristicsf the Control and Heart Failure Patients
Table 1 Baseline Characteristicsof the Control and Heart Failure Patients
Variable
Control
(n  6)
CRT
(n  24) p Value
Clinical characteristics
Age (yrs) 61  5 68  2 NS
Gender (% male) 6 (100) 21 (87) NS
Etiology (% ischemic cardiomyopathy) 6 (100) 13 (55)
NYHA functional class (n)
III — 8 0.001
IV — 16 0.001
ICD implantation (%) — 6 (25)
Hemodynamic parameters
LVEDD (mm) 51  3 66  3 0.004
LVEDV (ml) 158  27 315  29 0.018
EF (%) 72  4 25  2 0.001
LV dyssynchrony (ms) — 55  7
InterV dyssynchrony (ms) — 57  7
Medical therapy (%)
Beta-blockers 3 (50) 23 (95) 0.001
ACE-I 0 (0) 24 (100) 0.001
Loop diuretics 0 (0) 24 (100) 0.001
Spironolactone 0 (0) 20 (85) 0.001
CE-I  angiotensin-converting enzyme inhibitors; CRT  cardiac resynchronization therapy; EF 
jection fraction; ICD  implantable cardioverter-defibrillator; InterV  interventricular; LV  left
entricular; LVEDD  left ventricular end-diastolic diameter; LVEDV  left ventricular end-diastolic
olume; NYHA  New York Heart Association.ended to have lower LV dyssynchrony and mitral regurgi-
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Myocardial Gene Expression and CRT January 15, 2008:129–36ation but more significant interventricular dyssynchrony
nd larger LV volumes compared with responders. At
ollow-up, responders showed a greater increase in LVEF
nd a greater reduction in LV end-diastolic dimensions and
olume, whereas LV and interventricular dyssynchrony were
educed to a similar extent in both groups. Serum Nt-
roBNP levels decreased significantly in responders and
emained unchanged in nonresponders.
At baseline, LV mRNA levels PLN and -MHC were
imilar between responders and nonresponders. There was a
on significant trend towards lower SERCA and -MHC
ene expression and higher BNP gene expression in re-
ponders versus nonresponders.
At follow-up a significant increase in mRNA of
-myosin and in the ratio of -/-MHC was noted in
esponders in parallel to a reduction in mRNA levels of
NP. The -/-MHC ratio was significantly higher in
esponders versus nonresponders (p  0.05). In responders,
aseline mRNA Expression of the Control and Heart Failure Patient
Table 2 Baseline mRNA Expression of the Control and Heart Fa
Gene Expression (Relative Units) Control Subjects (n  6
SERCA (median; 25%–75%) 4.08 1.34 (2.76; 1.83–7.63
PLN (median; 25%–75%) 11.65 2.02 (10.87; 7.29–16
-MHC (median; 25%–75%) 2.22 0.51 (2.17; 0.99–3.48
-MHC (median; 25%–75%) 66.02 16.69 (57.90; 37.66–
BNP (median; 25%–75%) 0.13 0.06 (0.08; 0.01–0.30
ata are normalized for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expressed as r
-MHC -myosin heavy chain; -MHC -myosin heavy chain; BNP brain natriuretic peptide
TPase 2.
erial LV Endomyocardial mRNA Expression,chocardiographic, nd Functional Characteristicsn the CRT Po ulatio
Table 3
Serial LV Endomyocardial mRNA Expression,
Echocardiographic, and Functional Characteristics
in the CRT Population
BL (n  17) FU (n  17)
p Value
BL vs. FU
Hemodynamics
EF 24 1 39 2 0.001
LVEDD (mm) 68 3 63 4 0.014
LVEDV (ml) 291 24 183 17 0.001
LV dyssynchrony (ms) 53 6 27 3 0.001
InterV dyssynchrony (ms) 64 9 17 3 0.001
MR grade 2 (%) 75 25 0.001
Functional
NYHA functional class 3.4 0.1 2.6 0.1 0.001
Nt-proBNP (pg/ml) 2,897 495 1,480 303 0.003
Gene expression
SERCA (U) 1.392 0.16 1.54 0.12 NS
PLN (U) 6.56 0.38 6.75 0.40 NS
SERCA/PLN 0.21 0.02 0.23 0.02 NS
-MHC (U) 1.01 0.21 1.28 0.4 NS
-MHC (U) 33.60 2.33 31.72 2.99 NS
-/-MHC 0.03 0.01 0.04 0.01 NS
BNP (U) 16.77 3.07 6.09 1.27 0.005
esponders and nonresponders. Gene expression data are normalized for GAPDH and expressed
s relative units.
BL  baseline; FU  4-month follow-up; LV  left ventricular; MR  mitral regurgitation;b
t-proBNP  N-terminal part of the pro brain natriuretic peptide; other abbreviations as in Tables
and 2.V SERCA message levels increased together with the
ERCA/PLN ratio. In contrast, no significant changes in
ene expression were noted in nonresponders.
ariability of gene expression. In 3 patients biopsy sam-
les from different sites of the LV were used. In these
atients the variability of SERCA, PLN, BNP, -MHC,
nd -MHC mRNA concentrations were 10  4%, 12 
%, 33  6%, 12  5%, and 18  5%, respectively.
iscussion
he present study is the first to investigate the effects of
RT on established molecular structural and calcium reg-
latory markers of HF in human subjects. Our findings
emonstrate that the beneficial effects of CRT on LV
unction and remodeling are associated with “reversed
olecular remodeling” characterized by an increase in ex-
ression of genes regulating excitation-contraction coupling
nd a reversal of the isoform switching of the contractile
enes. These data suggest that gene expression profile in
uman HF patients—receiving optimal medical therapy
ith angiotensin-converting enzyme inhibitors, beta-
lockers, and spironolactone—is at least partially reversible
nd that molecular changes in structural and functional
roteins might contribute to favorable effects of CRT on
yocardial performance.
F and myocardial gene expression. Activation of so-
alled “fetal gene program” is the best-described myocardial
olecular alteration relevant to the pathophysiology of HF.
t is characterized by isoform switching in the expression of
enes regulating contractile proteins and the down-
egulation of genes regulating excitation-contraction cou-
ling (22,23). Although an altered molecular profile is part
f an adaptive response to persistent mechanical overload,
hanges in contractile proteins are responsible for depressed
erformance and contribute to further negative LV remod-
ling and failure. This is corroborated by single cardiac
yocytes or isolated heart experiments showing negative
notropic effects secondary to increased expression of the
low -MHC isoform (24,25). Accordingly, it was postu-
ated that only those therapeutic strategies that interfere
ith or reverse these molecular changes will result in an
ffective functional improvement and survival benefit in
ongestive HF patients (5,26). This postulate is supported
Patients
Heart Failure (n  24) p Value
1.47 0.15 (1.27; 0.97–1.57) 0.002
6.47 0.53 (6.06; 4.69–7.94) 0.002
1.12 0.21 (0.73; 0.40–1.50) 0.037
0) 32.58 3.46 (29.24; 22.78–40.93) 0.005
13.18 2.60 (8.75; 2.39–22.16) 0.014
units.
messenger ribonucleic acid; PLN phospholamban; SERCA sarcoplasmic reticulum calciums
ilure
)
)
.99)
)
108.5
)
elativey experimental studies demonstrating improved contractil-
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January 15, 2008:129–36 Myocardial Gene Expression and CRTty after adenoviral gene transfer of SERCA in animal
odels of HF or failing human cardiac myocytes (27,28).
ikewise, increased SERCA levels relative to PLN mRNA
evels were associated with improved SERCA mediated
a2 sequestration and enhanced systolic function (4,29).
erial LV Endomyocardial mRNA Expression, Echocardiographic,nd Functional Char cteristics in Responders and Nonresponders t
Table 4 Serial LV Endomyocardial mRNA Expression, Echocardand Functional Characteristics in Responders and Non
Responders (n  11)
BL FU
Hemodynamics
EF (%) 23 1 35 3
LVEDD (mm) 68 4 61 4
LVEDV (ml) 290 26 191 21
LV dyssynchrony (ms) 69 9 28 3
InterV dyssynchrony (ms) 61 10 18 5
MR grade 2 (%) 36 0
Functional
NYHA functional class 3.4 0.5 2.3 0.5
Nt-proBNP (pg/ml) 3,334 692 1,634 322
Gene expression
SERCA (U) 1.19 0.11 1.50 0.13
PLN (U) 6.28 0.46 6.4 0.56
SERCA/PLN 0.19 0.01 0.24 0.02
-MHC (U) 0.69 0.10 1.14 0.26
-MHC (U) 32.29 2.99 28.67 3.80
-/-MHC 0.021 0.005 0.044 0.008
BNP (U) 19.76 3.33 6.79 1.27
ene expression data are normalized for GAPDH and expressed as relative units. *p  0.05 follow
aseline nonresponders versus responders.
Abbreviations as in Tables 1, 2, and 3.
Figure 1 LV Endomyocardial Expression of Functional and Cont
Left ventricular (LV) endomyocardial expression of functional and contractile genes
responders. Data are normalized for glyceraldehyde 3-phosphate dehydrogenase (G
-myosin heavy chain; BNP  brain natriuretic peptide; PLN  phospholamban; SERT and myocardial gene expression. Cardiac resyn-
hronization therapy is associated with improved perfor-
ance and survival in patients with advanced HF and
lectromechanical dyssynchrony (11,13,30). Nevertheless,
pproximately one-third of these patients do not exhibit any
T
phic,
nders to CRT
p Value
L vs. FU
Nonresponders (n  6)
p Value
BL vs. FUBL FU
0.001 20 3 23 1* 0.004
0.003 71 4 69 4 0.056
0.001 343 69 304 56* 0.070
0.002 40 4 27 6 0.154
0.003 79 17 14 4 0.013
0.010 14 1 0.034
0.00210 3.4 0.5 3.1 0.4† NS
0.032 2,230 703 1,153 1012 NS
0.032 1.64 0.35 1.60 0.27 NS
NS 6.70 0.68 7.41 0.46* NS
0.012 0.23 0.03 0.22 0.04 NS
0.035 1.40 0.48 1.52 1.13 NS
NS 32.55 4.73 37.32 4.26 NS
0.018 0.041 0.010‡ 0.040 0.030* NS
0.002 10.65 5.08 4.79 2.86 NS
responders versus responders; †p  0.01 follow-up nonresponders versus responders; ‡p  0.05
le Genes
seline (open bars) and at 4-month follow-up (solid bars) in responders and non-
) and expressed as relative units. -MHC  -myosin heavy chain; -MHC 
sarcoplasmic reticulum calcium ATPase 2.o CR
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Myocardial Gene Expression and CRT January 15, 2008:129–36enefit from this therapy. We hypothesized that reversed
V remodeling and improved myocardial performance in
atients undergoing resynchronization therapy was associ-
ted with changes in established molecular structural and
alcium regulatory markers of HF. As expected, before
RT, HF patients showed altered expression of genes that
egulate Ca2 handling and contractile proteins as com-
ared with control subjects. Of note, in the entire popula-
ion, CRT was not associated with changes in gene expres-
ion of these proteins. Only the subgroup of patients with
mproved LV function, reversed LV remodeling, and reduc-
ion in NYHA functional class, categorized as responders to
RT, demonstrated an increase in expression of the fast
-MHC and an increase of the -myosin/-MHC mRNA
atio. Moreover, in these responders, improved myocardial
erformance was associated with a significant increase in LV
ERCA mRNA levels and in the SERCA/PLN ratio as
ompared with baseline. In contrast, the absence of LV
emodeling and functional beneficial effects of CRT in
onresponders was associated with no changes in the gene
rofile of the structural or calcium regulatory proteins.
urthermore, the significant reduction of serum Nt-
roBNP levels in all patients was paralleled by a significant
own-regulation of myocardial BNP gene expression only
n the responders. Our observations are consistent with
xperimental studies demonstrating beneficial effects of
olecular intervention on myocardial performance (27,28).
n addition, they corroborate previous observations demon-
trating increased expression of fast -myosin isoform or
alcium handling proteins after beta-blocker therapy or LV
nloading with assist devices (6,10). Taken together, these
bservations support the postulate that interventional ther-
pies in HF could lead to sustained functional and clinical
mprovement only if they will efficiently alter adverse
olecular remodeling.
Interestingly, we noticed a trend toward higher mRNA
xpression of -MHC and SERCA in the nonresponders at
Figure 2 LV Endomyocardial Gene Expression of BNP Gene
The LV endomyocardial gene expression of BNP gene at baseline (open bars)
and at 4-month follow-up (solid bars) in responders and nonresponders. Data
are normalized for GAPDH and expressed as relative units. Abbreviations as in
Figure 1.aseline as compared with responders, indicating that de- Spite a similar degree of LV dysfunction, dyssynchrony, or
linical HF class, nonresponders had paradoxically a better,
more favorable,” molecular profile of established structural
nd calcium regulatory markers at baseline as compared
ith responders. This seems to indicate that these patients
ere less sick in terms of “the molecular remodeling,” and
herefore less prone to improve after CRT. In addition, this
ndirectly suggests that the current selection criteria based
n clinical, electrocardiographic, and echocardiographic-
erived parameters are not sufficient enough to predict the
ndividual response to CRT. We speculate that baseline
ene expression profiling might be a new and more accurate
ool in predicting the response to CRT therapy. Further
tudies using large scale microarray profiling are needed to
ddress this hypothesis and identify novel molecular mark-
rs predictive of reversed remodeling after CRT.
Our study, similar to previous clinical reports on the
ffects of beta-blocker therapy (10), does not address caus-
tive or mechanistic relationship between LV remodeling
fter CRT and molecular changes. Nevertheless, LV dys-
ynchrony and increased neurohormonal activation are as-
ociated with down-regulation of contractile regulating
enes (31–34). A more synchronous contraction together
ith the reduction of muscle sympathetic nerve activity
oinciding with reduced levels of catecholamines in re-
ponders to CRT (35,36) might thus account for the
bserved molecular changes. Alternatively, the reduced wall
tress induced by LV remodeling after chronic CRT reduces
he stretch-induced up-regulation of BNP, which benefi-
ially affects LV remodeling. This hypothesis is supported
y our observation of inverse relationship between BNP and
F and positive correlation between SERCA and EF, and
previous report on BNP-mediated reduction in SERCA
ene expression indirectly supports this hypothesis (31).
he extent to which the restoration of synchrony, LV
emodeling, and reduced neurohormonal activation contrib-
te to the observed molecular remodeling requires further
nvestigation. Experimental studies with serial endomyocar-
ial biopsies could unravel the time- and spatial-myocardial
elationship of relevant molecular changes and further
lucidate causative mechanisms underlying CRT-induced
olecular changes.
tudy limitations. First, LV dyssynchrony generates alter-
tions in transmural and transchamber protein expression,
hich are most prominent in the late-activated, high-stress
ateral endocardium (32) and might cause differences in
egional gene expression (33). To limit the impact of
egional differences, LV biopsies were obtained from the
picoseptal regions in all patients at baseline and at follow-
p. Furthermore, multiple biopsies were procured from
arious LV sites in 3 patients. In these patients, the
ariability in SERCA, PLN, -MHC, -MHC, and BNP
RNA levels in the different biopsies were minimal. Thus,
n the current study, gene expression data seem to reflect
lobal rather than local changes related to LV remodeling.
econd, the underlying etiology of HF might affect the
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nderpowered to compare smaller subgroups, no difference
n gene expression was noted between HF patients with
schemic versus idiopathic dilated cardiomyopathy. In ad-
ition, the variability was limited by performing paired
omparisons in samples from the same individuals. Third, as
xpected, the dose of diuretics had to be adapted following
RT. In contrast, the dose of beta-blocker and angiotensin-
onverting enzyme inhibitor therapy remained unchanged,
nd there were no differences in HF medication between
esponders and nonresponders excluding potential drug
ffects on remodeling. Fourth, only RNA analysis and no
rotein analyses or functional activity studies of calcium
andling genes were possible, owing to the small size of the
V biopsies. In this regard, it should be noted that the
elationship between transcriptional and translational
hanges in SERCA expression is controversial. Neverthe-
ess, an increase in SERCA gene expression was concomi-
ant with the functional improvement in responders, sug-
esting that the increase in SERCA message was
unctionally meaningful. Fifth, although GAPDH is gen-
rally accepted as a very reliable housekeeping gene, we do
dmit that doing the whole procedure again with another
ousekeeping gene could add some incremental value to the
tudy and compensate for variability in the gene expression
f the housekeeping gene itself (37). However, lack of tissue
amples made this impossible. Finally, although we clearly
emonstrated improved expression of the most established
olecular markers of HF, it is likely that many other
elevant genes are participating in the complex tissue re-
odeling and need to be identified in studies using microar-
ay analysis.
onclusions
n congestive HF patients responding to CRT, an improve-
ent in LV function and reduction in NYHA class are
ssociated with “reversed molecular remodeling,” charac-
erized by increased expression of contractile and calcium
egulatory proteins. This suggests that reversed “molec-
lar remodeling” might be the key mechanism contrib-
ting to sustained improvement in LV function and
urvival after CRT.
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